Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@article{Rhyasen2013TargetingIA,
  title={Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.},
  author={Garrett W Rhyasen and Lyndsey C. Bolanos and Jing Fang and Andr{\'e}s Jerez and Mark E. Wunderlich and Carmela Rigolino and Lesley Mathews and Marc Ferrer and Noel Southall and Rajarashi Guha and Jonathan Keller and Craig E. Thomas and Levi J. Beverly and Agostino Cortelezzi and Esther Natalie Oliva and Maria Cuzzola and Jaroslaw Maciejewski and James C. Mulloy and Daniel T. Starczynowski},
  journal={Cancer cell},
  year={2013},
  volume={24 1},
  pages={90-104}
}
Myelodysplastic syndromes (MDSs) arise from a defective hematopoietic stem/progenitor cell. Consequently, there is an urgent need to develop targeted therapies capable of eliminating the MDS-initiating clones. We identified that IRAK1, an immune-modulating kinase, is overexpressed and hyperactivated in MDSs. MDS clones treated with a small molecule IRAK1 inhibitor (IRAK1/4-Inh) exhibited impaired expansion and increased apoptosis, which coincided with TRAF6/NF-κB inhibition. Suppression of… CONTINUE READING